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Triple Negative Breast Cancer (TNBC) is defined as negative for three genes,
estrogen receptor (ESR), progesterone receptor (PR) and Human epidermal growth factor
receptor (HER2-neu) genes. Previous data show the V-Myb Avian Myel oblast Viral
Oncogene Homolog Like 1 (MYBL1) gene is over-expressed in Triple negative breast
cancer cell line (MDA-MB231). MYBL1 belongs to the MYB family of genes which are
transcription factors and proto-oncogenes which are associated with cell cycle regulation,
apoptosis, and differentiation, all of which are key events associated with cancers. It could
be that MYBL1 contributes to these same processes in TNBC. Instead of studying
MYBL1’s contribution to several of these processes, we were mainly concerned with
identifying genes that were either directly or indirectly affected by down-regulation of
MYBL1 gene. Utilizing a gene silencing approach helps to identify genes that cooperate
with MYBL1 in the signaling processes in cancer. Although the focus of our laboratory is
TNBC, there are two parts to this current study, one that examines MYBL1 in luminal
cancers cell line (MCF7) and one that examines MYBL1 in TNBC, designated Part 1 and
Part 2, respectively.
1

2
For Part 1, we performed analyses of MCF7 (Luminal breast cancer cell line) receptor
positive cells where estrogen receptor gene was silenced; and another MCF7 preparation
where cMYB gene was silenced. Both datasets were obtained from Gene Expression
Omnibus (GEO).
These datasets were chosen because even though they were neither TNBC or
directly involved MYBL1 as the primary target, comparative analyses of both datasets
showed MYBL1 knock-down (KD). We reasoned that even under these conditions, genes
either directly or indirectly associated with MYBL1 might be identified. For Part 2 of this
study, short hairpin RNA (shRNA) lentiviral transduction was used to down-regulate
MYBL1 in MDA MB231 TNBC cells. A substantial number of reliable differentially
expressed genes were identified here. Overall, genes recognized as associated with
MYBL1 in the MCF7 luminal preparations (Part 1) were drastically different from genes
identified as associated with MYBL1 in the TNBC KD study (Part 2). In both datasets, we
identify novel genes that appear to be coordinately expressed with MYBL1 in breast
cancers. This study led to identification of candidate genes that might be important towards
the study of characterizing MYBL1 expression in TNBC. Two of these genes, transcription
factor 19 (TCF19) and Kinesin-like protein (kinesin family member 18B) (KIF18B) have
been experimentally validated. MYBL1 is a strong candidate gene to study for its
contribution to the development of TNBC. Continued analyses of these genes and their
relationship to MYBL1 should lead to a better understanding of signaling processes in
breast cancers.
Keywords: Breast Cancer, Triple Negative, MYBL1 knock-down.
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CHAPTER 1
INTRODUCTION
BREAST CANCER TYPES:
The progression of adult-onset cancers is a long process involving genetic changes
that happen over an extended period of time. These changes are specifically related to
alterations in cell growth, programmed cell death and ultimately cellular differentiation so
as to define the disease as a cancer (as opposed to some other disease such as diabetes or
muscular dystrophy) [1]. For breast cancers, the initial and subsequent changes occur in
cells associated with breast tissues. For many breast cancers the progenitor cell types have
not been identified and characterized. But one can speculate that the progenitors and
patterns leading to pathogenesis are different in each of different breast cancer types.
Breast and other cancers tend to be heterogenous and genetically complex. As
evidence, a brief description of the ‘types of breast cancers’ are summarized below.
Although there are many different types of breast cancer, most are rare (see below). As a
general description, benign samples are in situ and non-life threatening, and the invasive
cancers metastasize to distal organs and are thereby malignant. The recurring cancers recur
at the same or different locations. Similar to other cancers, breast cancers are described and
diagnosed based on pathological diagnoses and molecular subtype analyses [2]
(https://www.breastcancer.org/symptoms/types). Cancers characterized based on their
1
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molecular signatures were often identified using gene expression microarray studies. The
microarray experimental platform has been instrumental in defining the gene expression
profiles and identifying potential therapeutic targets useful for treating different cancers.
Detailed List of the Different Types of Breast Cancers Based on Pathological
Diagnoses:
Ductal Carcinoma in Situ (DCIS): DCIS is a non-invasive carcinoma, that
originates in the milk ducts of the breast. Although the cancers do not metastasize, DCIS
patients have an increased risk of developing invasive cancers later.
Invasive Ductal Carcinoma (IDC): IDC is the common type of breast cancer,
detected in ~80% of breast cancers. IDC is an invasive, infiltrating ductal cancers,
occurring in the milk ducts of patients.
Tubular Carcinoma of the Breast: Tubular carcinomas are a subtype of the IDC
cancers. They have a tube-shaped tubular configuration, but they also originate in the milk
ducts. These tumors occur in 8%-27% of patients.
Medullary Carcinoma of the Breast: Medullary carcinomas are rare invasive
ductal carcinomas. They appear as soft, fleshy masses resembling the brain’s medulla.
They occur in about 3% of patients.
Mucinous Carcinoma of the Breast: Mucinous Cancers are rare cancers that also
begin in the milk ducts. The cancers are defined as abnormal cells ‘floating in pools of
mucin’.
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Papillary Carcinoma of the Breast: Papillary cancers are also rare (~1-2%)
invasive carcinomas. The cancers have well defined borders with small finger-like
projections.
Cribriform Carcinoma of the Breast: Cribriform cancers are also rare invasive
cancers. The cancers are low grade (i.e., look normal), but appear to have ‘holes or display
cribriform-like configurations.
Invasive Lobular Carcinoma (ILC): ILC cancers are invasive cancers that begin
in the lobules of the breast. They are the second most common type of cancers occurring
in ~20% of patients.
Inflammatory Breast Cancer (IBC): IBC is a rare very aggressive, invasive
cancer. The cancers have the appearance of ‘sheets’ instead of lumps, which makes them
difficult to treat and detect.
Lobular Carcinoma in Situ (LCIS): LCIS is defined as an abnormal cell growth
in the lobules; often referred to as a neoplasia instead of carcinomas. The cancers remain
in the breast but are diagnostic for future invasive cancers.
Male Breast Cancer: Breast cancer in men is rare, occurring at a rate of less than
1%. The cancers tend to be small, but they can also be invasive.
Paget’s Disease of the Nipple: Paget’s disease is a rare breast cancer involving
cancer around the nipple and ducts draining towards the nipple.
Phyllodes Tumors of the Breast: Phyllodes cancers present as tumor cells that
grow in a leaf-like configuration. The cancer occurs in less than 1% of breast cancer
patients.
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Figure 1:

Summary of the Incidence of Breast Cancers Based on
Molecular Signatures (Burstein, Goldhirsch, St Gallen 2007)

Figure 2:

Diagram Demonstrating the Anatomical Location of the
Progenitor Cells Associated with Luminal Cancer Compared to
Basal-like TNBC [3]
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List of Breast Cancer Types Based on Molecular Analyses:
The incidence and description of breast cancers characterized based on
their molecular signatures are presented in Figure 1, and a more detailed
description is given below [2] (https://www.breastcancer.org/symptoms/types).
The more common breast cancer designations are often referred to as luminal or
Triple negative/basal-like subtypes. An explanation describing the anatomical
distinction between luminal compared to basal-like/triple negative is given in
Figure 2 [3].
Molecular Subtypes of Breast Cancer (Luminal A/B; triple
negative/basal-like; HER2-enriched; Normal-like): Luminal A cancers are
defined by molecular analyses to be estrogen receptor and progesterone positive
and HER2 negative. Luminal B are defined as estrogen receptor and progesterone
positive and HER2 positive. The prognosis is slightly worse than Luminal A.
Triple negative/basal-like are estrogen receptor, progesterone and HER2 negative.
Although TNBC and basal-like are defined together, (and share substantial overlap based on gene expression analyses), data show that there are molecular
differences between the subtypes. A more detailed description of TNBC is given
below. HER2-enriched cancers are estrogen receptor and progesterone negative
and HER2 positive. Normal-like are similar to Luminal A estrogen receptor and
progesterone positive and HER2 negative but have the appearance of low grade
with low nuclear protein Ki67 (Ki67) levels.
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Triple negative breast cancer: These cancers are estrogen receptor, progesterone
negative and HER2 negative. They represent ~15% of breast cancers. They are not
dependent on hormone regulation, have low 5-year survival, and lack suitable targeted
therapies. Data suggest that their progenitor cells are associated with the basement region
of the ducts, compared to luminal cancers which border the luminal breast regions (Figure
2). Even though TNBC are characterized based on receptor-negative status, Lehmann et
al., [4] show that TNBCs can be further divided into six sub-categories based on molecular
signatures and clustering patterns identified using microarray. These data emphasize the
heterogeneity and complexity of the cancers. Lehmann grouped TNBC into cancers
designated as Luminal androgen receptor (LAR) or molecular apocrine cancers, two basallike types (BL1 and BL2), an immunomodulatory group, a mesenchymal (M) group and a
mesenchymal stem-like (MSL) subtype. The LAR sub-category includes estrogen receptor
samples with over-expression of androgen receptor, and other genes involved in hormonal
regulation. The basal type 1 (BL1) includes over-expression of genes involved in pathways
related to Ribonucleic acid (RNA) polymerase processes, cell cycle regulation and cell
division. Samples characterized as Basal type 2 (BL2) genotype are thought to be of
myoepithelial origin, including genes associated with growth factor signaling processes,
gluconeogenesis, and glycolysis. Cells characterized in the immunomodulatory (IM)
category appear similar to medullary breast cancers and are enriched in genes involved in
immune signaling pathways, natural killer cell pathway, cytokine signaling, and antigen
identification and processing. The M and MSL groups are enriched in genes associated
with cell motility, proliferation, mesenchymal-like differentiation, extra-cellular matrix
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proteins. Collectively, the complexity of the breast cancer subtype data explains (in part)
why patients differ in their response to therapies.
Information Related to Breast Cancers Aligned with Our Research Goals:
There is a 3% chance that a woman will die from breast cancer and less than 1%
chance for men. In 2020, an estimated 276,480 new cases of invasive breast cancer will be
diagnosed in women and 2820 new cases in men (https://www.breastcancer.org). Of the
276,480 cases, approximately10-20% are receptor-negative, TNBC. Considering all breast
cancer types, approximately 43,170 women and 522 men diagnosed with breast cancer are
estimated to die in 2020. Conventional hormone therapy (e.g. tamoxifen) and anti-HER2
antibody therapy targeted treatments (e.g. trastuzumab) exist for receptor positive cancers,
but because TNBC lack these targeted genes, therapies like tamoxifen and trastuzamab are
not effective [5]. TNBC patients have few therapeutic options, having to basically rely
upon chemotherapy and radiation therapies [6]. As a result, there is a need to further
characterize TNBC and identify genes key to the tumorigenic process. Once novel genes
have been identified, they can be considered as targeted strategies to combat breast cancers
and ultimately used as therapies to save lives.
In recent years, MYBL1 is looking like a good candidate to study for its possible
contribution to the pathogenesis in TNBC. MYBL1 is a putative oncogene and a key gene
involved in regulation of cell proliferative, differentiation and apoptosis, processes which
are hallmarks of cancers. Data from our laboratory and others show that the MYBL1 gene
is differentially expressed in TNBC and other cancers [7] [8]. Although the goal of the
current studies is to provide insights into signaling processes related to the MYBL1 gene
in TNBC cells, we also designed experimental approaches to identify genes associated with
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MYBL1 in datasets generated using receptor-positive cancer cells. Two receptor-positive
knockdown studies were retrieved from Gene Expression Omnibus (GEO) [9] based on
their experimental objectives.
Both studies were designed with the goal of identifying genes affected by silencing
the cMYB gene. cMYB belongs to the MYB family of genes which also includes MYBL1
and MYBL2. Data show that the MYB family of genes are co-expressed in a variety of
different cancer cell lines and patient samples [10] [11] [12]. If cMYB is selectively
silenced in the two GEO datasets, then MYBL1 (and MYBL2) should also be downregulated, and If MYBL1 is down-regulated, we expect genes directly and indirectly
affected by MYBL1 are coordinately affected. Consistent with previous observations,
cMYB, MYBL1 and MYBL2 were each down-regulated in the GEO datasets. So, we
proposed that these studies could be used to identify genes affected by down-regulation of
MYBL1 and results of these data would lead to a better understanding of MYBL1 related
processes in breast cancers. The GEO datasets were used in Part 1 of the current study and
a separate analysis (Part 2) was designed to determine processes specifically related to
MYBL1 expression in TNBC samples.
It’s estimated that over 92 different breast cancer and non-tumorigenic cell lines
are available [13]. The cell lines are characterized by their molecular signatures, invasive
potential, site of origin and morphological properties just to note some characteristics.
Often Luminal cell types (i.e., MCF7) are compared to TNBC (i.e., MDA MB231) because
the two molecular subtypes represent receptor positive compared to receptor negative
genotypes. Like many other studies, for the project described in this document, Luminal
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type cancer cells were chosen for comparison to TNBC cells and samples. Both are cancers,
but they are divergent with respect to receptor status and morphological characteristics.
Use of the MCF7 cell line data compared to the MDA MB231 datasets also allow
for comparison to well documented published data. For many of the experiments outlined
in the current project, data generated using MCF7 cells were compared to data generated
using MDA MB231 cells.

CHAPTER 2
LITERATURE REVIEW
BACKGROUND
Discovery of the MYB Family Genes
The focus of this study is to better further characterize MYBL1 in breast cancers.
MYBL1 belongs to the MYB family of genes which include cMYB, MYBL1 and MYBL2.
The c-MYB gene was the first of the MYB family members to be discovered based on its
similarity to the Avian Myeloblastosis Virus (AMV) v-myb gene sequence [14]. AMV is
a highly oncogenic chicken leukemia virus which is capable of transforming immature
hematopoietic cells. Compared to c-MYB, AMV has truncations in both N-terminal and
C-terminal regions and contains 16 intragenic point mutations. The MYBL1 and MYBL2
genes were identified later after a Complementary DNA (cDNA) library was screened
using the c-MYB sequence (11).

Data show that cMYB, MYBL1 and MYBL2

demonstrate both similar and different patterns of expression under various conditions.
Unique to MYBL1, the gene is a master regulator in the meiosis phase of the cell cycle in
testis (12), and thus demonstrates high levels in normal testes undergoing spermatogenesis.
Although not entirely unique to MYBL1, the gene regulates expression of small RNAs
which control epigenetic and post-transcriptional silencing processes [15].
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Comparative Analyses of MYB Family Sequences as Explanation of Their
Shared Gene and Unique Gene Expression Properties
The MYB genes share both similarities and differences upon comparison of their
protein sequences. The genes share an N-terminal DNA binding domain (DBD), an internal
transactivation domain and C-terminal regulatory domain [16, 17]. The domains are
particularly important for directing DNA binding and protein: protein interactions with coactivators, transcription factors and other proteins. The DBD located at the N-terminus is
highly conserved in the family of genes, and the transactivation and C-terminal regulatory
regions are less conserved and functions as transactivation domains. The positions of these
regions can be demonstrated using the NCBI Web CD Search Tool [18].
There is greater than 90% similarity between the DBD in MYB family of genes.
Each contains the SANT (Swi3, Ada2, N-Cor, and TFIIIB) domain, which is critically
important as a DNA-chromatin recognition sequence, allowing for chromatin remodeling,
and subsequent transcriptional regulation. This region implicates epigenetic regulation of
MYBL1. The SANT domain is defined by binding to SW13, ADA2, N-CoR and TFIIIB
genes which in turn bind proteins with MYB-like G-C rich motifs. The DBD region is
involved in both activation and transcriptional repressor complexes [16].
Because the MYB family of proteins share incredible homology in their conserved
DNA binding domain, on some level they interact with some of the same genes. Rushton
et showed that MYB family genes recognize some of the same reporter gene constructs in
in vitro transfection studies [11] . Compared to the N-termini, the transactivation and Cterminal region are less well conserved in MYB family proteins. Data show the N-termini
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of c-MYB are involved in intra and inter negative regulator functions and truncation of the
C-terminal regions result in tumors [19].
Some investigators suggest that differences in the C-terminal region is a key reason
the MYB genes can display different signaling mechanisms and ultimate functions.
Differences in the domains coupled with the different overall sequences of the MYB family
genes, emphasize the complex signaling network of the MYBL1 genes.
Expression of MYBL1 in Various Tissues and its Relationship to the
Cell Cycle Signaling and Tumorigenesis
Relationship of MYBL1 to cell cycle: Because the MYB family of genes are
putative oncogenes [20] and function in processes key to dysregulation of the cell cycle
and ultimately to tumor progression, they are likely candidates to study in search of targeted
therapies. The c-MYB gene was previously considered as a target for luminal breast cancer
therapy because (a) the gene is highly expressed in these tissues, (b) it is critical to growth
and a key gene in cell cycle signaling, and (c) the gene leads to tumors in in vitro studies
[21]. Until several years ago, small molecules and c-MYB RNA interference (RNAi ) were
examined as targeted therapeutic approaches [22] in pre-clinical studies. These studies
have since been discontinued, but it could be that MYBL or even MYBL2 are more suitable
candidates to study for a more prominent role in cancers. Less is known about MYBL1
because there are fewer studies related to MYBL1 compared to c-MYB. Some of the first
experiments performed on characterization of MYBL1 involved analyses of the gene in
cell cycle signaling, so the genes involvement in cell cycle signaling is well documented.
Ziebold et al., [23] performed one of the earliest experiments linking MYBL1 to the cell
cycle processes. Their studies show that MYBL1 is involved in GAP 1 phase (G1) to
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Synthesis (S) phase progression and activation is via phosphorylation of the C-terminus by
cyclin dependent kinases. Studies by Marharmati et al., [24] show that MYBL1 cooperates
with MYC to mediate progression to S phase in smooth muscle cells.
Emphasizing the complexity of the involvement of MYBL1 in the human signaling
mechanisms, the cell cycle can be regulated by various interactions between Elongation
factor 4 (E2F4), Elongation factor 5 (E2F5), LIN9 complex DREAM MuvB core complex
component (LIN9), Lin-37 DREAM MuvB Core Complex Component (LIN37), Lin-52
DREAM MuvB Core Complex Component( LIN52), Lin-54 DREAM MuvB Core
Complex Component (LIN54), MYBL1, MYBL2, Retinoblastoma-Like 1 Protein (RBL1),
Retinoblastoma-Like 2 Protein (RBL2), Retinoblastoma Binding Protein 4 (RBBP4) ,
Transcription Factor Dp1 (TFDP1) and Transcription Factor Dp2 (TFDP2) proteins which
collectively are designated as DREAM or LINC complexes [25, 26]. Progression from S
phase is dependent on the formation of subcomplexes between LIN9, LIN37, LIN52,
LIN54 and MYBL2. Of the genes listed above, E2F4, LIN37 and TFDP2, MYBL2 and
MYBL1 (of course) were dysregulated in data described in the current knockdown study.
Description of E2F4 in the current project will be addressed in the Results section of this
document.
Relationship of MYBL1 to tumorigenesis: Studies show the MYBL1 gene in tumors
is activated by amplifications, rearrangements, and translocation events [7, 27, 28] ; often
translocations involve fusion with the Nuclear Factor I B (NFIB) gene. Although the
precise mechanism has not been defined in all cases, data show MYBL1 dysregulation in
Burkitt’s’ lymphoma [29, 30], Cutaneous Adenocystic Carcinoma [31], triple negative
breast adenoid cystic carcinoma [27] and TNBC in Player et al.,studies [8]. Arsura et
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al.,[29] showed that MYBL1 downstream interactions with MYC gene promotes G1 to S
phase transition and increased survival in lymphomas. Their data demonstrate the
relationship between MYBL1, cell signaling, apoptosis and cancers.
Liu et al., [21] examined 181 patient breast cancers via microarray and performed.
Supervised Network Analyses with the goal of determining prognostic significance of cMYB in receptor positive cancers. Along with cMYB, the authors determined the relevance
of MYBL1 in the different breast cancers. Utilizing multivariant analysis methods, Liu et
al. identified MYBL1 and 9 other genes associated with poor prognosis in receptor positive
samples. Four of the 9 genes identified by Liu et al. were identified as differentially
expressed in the current receptor negative MYBL1 knockdown dataset including Repressor
of RNA polymerase III transcription MAF1 (MAF1), Dual Specificity Phosphatase
(DUSP7), and Solute Carrier Family 25 Member 1(SLC25A1), with Ran GTPase
Activating Protein 1(RANGAP1) data not shown. Gorbatenko et al., [32] examined
MYBL1 expression in basal compared to normal and luminal breast samples. Gorbatenko
et al., found higher levels of MYBL1 in basal tumors (Figure 3 [arrow]). Note, MYBL2
and MYBL1 demonstrated similar expression in basal cells. Basal-like cells are closely
related to TNBCs (based on gene expression analyses and morphology). Player et al.,
observed a similar pattern of expression in TNBC patient
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Figure 3 continued
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Figure 3:

Gorbatenko Data [32] Analyses of Breast Cancer Subtypes for
Expression of HER2, cMYB, MYBL1 and MYBL2 Expression in
Patient Samples
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Figure 4:

Hierarchical Clustering (HC) Analyses to Demonstrate MYBL1
Expression in Patients (Maire dataset).
(a)
(b)

Figure 5:

Red bar=TNBC patients (region under arrow). Note that most of
red bar is cluster together (with most of the TNBC ‘clustering
together’) based on these 6 genes.
these are the same TNBCs omitting the genes that do not cluster
together. Red region under the bar indicates over-expression of
genes. There is a single line of green corresponding to downregulation of GATA3 which is known to be down regulated in
TNBC. 168 patients across top of HC [8].

Experiment Outline of Part 1 and Part 2 of Current Study
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Part 1 Summarized
When we began this study, we performed an extensive search of GEO in an attempt
to identify previously published datasets where MYBL1 was silenced in TNBC; none
existed. However, we did find ‘gene silencing’ datasets where MCF7 luminal cell line was
the host cell and MYBL1 was indirectly affected by the knock-down process. DNA
microarray is commonly used to identify differentially expressed genes associated with
these processes. So, in addition to searching for knock-down studies, we included filters
that included ‘microarray analyses’ as the experimental platform. Dr Audrey Player has
generated a substantial number of breast cancer microarray datasets, so studies in GEO that
use microarrays would allow direct comparison to result in her datasets. Two different
studies were identified in GEO. One study involved shRNA silencing of estrogen receptor
(ESR1) in MCF 7, following by microarray analyses [33], and the other involved small
interfering RNA (siRNA) silencing of cMYB gene in MCF7 cells followed by custom
microarray analyses [34]. Both GEO datasets involved analyses of the MCF7 luminal
breast cancers, and both experiments lead to substantial down-regulation of cMYB,
MYBL1 and MYBL2; therefore, the datasets could be utilized to identify genes affected
by MYBL1 down-regulation.
As background, untreated MCF7 cells express all three MYB genes, and it has been
shown that ESR1 (if expressed, as it is in MCF7), can regulate co-expression of cMYB,
MYBL1 and MYBL2 genes [35]. Related to the cMYB siRNA experiments, cMYB was
directly targeted for silencing, and as expected MYBL1 and MYBL2 were coordinately
down-regulated. This is consistent with other studies that show that when the MYB family
of genes are co-expressed, they tend to be co-regulated to some extent; so, it is not
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surprising that knock-down of cMYB will lead to down-regulation of MYBL1 and
MYBL2. The objective of the current research is to characterize MYBL1. We understand
that analyses of MCF 7 datasets will lead to identification of MYBL1 related genes that
characterize luminal cancers. Still, we proposed that cross comparison of genes identified
as differentially expressed in the ESR1 knockdown compared to the cMYB knockdown
could lead to discovery of genes related to MYBL1 regulated processes across cell lines
(i.e., in luminal cancers and TNBC).
Part 2 Summarized
For Part 2, shRNA lentiviral was utilized to target MYBL1 in MDA MB231 cells.
An outline of the shRNA procedure is given in Figure 6 [36]. For Part 2, MDA MB231
cells were transduced with shRNA (Figure 7), screened and successful knock-downs were
analyzed via microarray (Figure 8)
https://tools.thermofisher.com/content/sfs/brochures/activity2_structure_function.pdf.
Genes identified as differentially expressed in Part 1 and Part 2 were then compared in an
effort to identify MYBL1 related genes. We proposed that this approach could lead to
discovery MYBL1 related genes (and processes) common to both luminal and TNBC.
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Part 2 Experimental Outline

Figure 6:

Experiment Outline of Part 2 of This Study

Figure 7:

Summary of shRNA Procedure
HEK cells are transfected with the transgene of interest, and all ciselements required for RNA production and packaging. Packaged
particles are generated, then harvested) and sent to customer for
transduction experiments [36]. In the figure above viral particles
generated by HEK293T cells are used to transduce cardiomyocyte cells.
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Figure 8:

The Affymetrix Microarray Genechip
Immobilized sense strands complementary to the target sequence are
on the genechip. Gene-chips containing either 56,000 transcripts or
186,000 transcripts, splice variants and small RNAs displayed as blue
dots in the middle figure. aRNA (or small RNA) is labeled and
hybridized to the genechip. High copy number corresponds to an
intense to intense probe-set signals; displayed as lighter spots in the farright magnified pane. Control sequences at known concentrations are
pane. Control sequences at known concentrations are also supplied on
the gene-chip and used for determination of copy number [37].

CHAPTER 3
DESIGN OF THE STUDY
Materials and Methods
Cell Lines
MCF7 (receptor positive luminal cells), MDA MB231 (receptor negative TNBC
cells) and MCF10A (receptor negative non-tumor) cell lines were utilized for the study.
All cell lines were purchased from American Type Culture Collection (ATCC®) atcc.org
(Manassas, VA, USA). The cells were cultured in Dulbecco’s Modified Eagle Minimum
essential media (DMEM) supplemented with 1% penicillin and 10% serum in a 37° C
incubator with 5% CO2 as suggested. The cells were fed twice weekly and harvested once
they obtained 80-90% confluency using a 0.25% trypsin solution (Millipore, Sigma, St.
Louis, MO, USA). The GEO breast cancer patient datasets included Maire et al., [38]
(GSE65216), Perou et al., [34] (GSE21371), and Muthukaruppan et al., [33] (GSE37820).
Ribonucleic Acid (RNA) Isolation
The cell lines utilized in this study were grown to approximately 90% confluence
in T75 dishes and harvested by adding Triazol to the culture dish and processed as
suggested ThermoFisher Scientific (Waltham, Massachusetts). As summary, whole cells
were lysed using 1 milliliter of Triazol, followed by addition of 200ul of chloroform.
Mixtures were centrifuged at 12,000 Revolutions Per Minute (RPM)
22
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to separate the aqueous top layer. The aqueous layer was removed, placed in a clean tube
and 500ul of 95% ethanol was added. This mixture was placed at -20°C for 30 minutes,
removed and centrifuged for another 30 minutes at 10,000 RPM. The RNA pellet was
collected and 20ul of clean water was added; to ensure mixing, the sample was heated at
~60°C for 1 minute.
One microliter (ul) was removed for spectrophotometry analyses of the 260/280
absorbance ratio. Suitable RNA values ranged between 1.8-2.0 ratio. An aliquot of the
RNA was also removed for gel electrophoresis. Up to 1 microgram (ug) of RNA was added
to RNA sample buffer, heated at ~60°C for 1 minute and separated on 1% agarose gel. The
RNA gel contained 1 gram of agarose, 1x 3-(N-morpholino) propane sulfonic acid (MOPs)
buffer, 2µl ethidium bromide and 7% formaldehyde.
Generating Complementary DNA (cDNA)
The cDNA was generated using iScript cDNA kit (Bio-Rad, Hercules CA, USA).
One microgram (ug) of the total RNA is added to a mixture of 5x buffer, reverse
transcriptase, random hexamers, The Dynabeads® Oligo dT mixture, deoxyribonucleic
triphosphate acids (dNTPs) and water to 20 microliters. The mixture was placed at 45°C
for one hour, followed by 85°C for 3 minutes inactivation of the reverse transcriptase. The
mixture was cooled, and 80ul of water was then added. The resulting cDNA was stored at
-20°C until ready for polymerase chain reactions.
Primer Generation
The primer3 [39] program (http://bioinfo.ut.ee/primer3-0.4.0/ ) was used to
generate the primer sequences for each of the target genes. Nucleotide sequences
corresponding to each of the target genes was obtained from Affymetrix NetAffx [37]

24
(http://www.affymetrix.com/estore/analysis/index.affx). For each gene, the resulting
amplicon sizes were designed so that the amplicon ranged from 200 – 300 nucleotides.
The

University

of

California

Santa

Cruz

Genome

database

[40]

(https://genome.ucsc.edu/) was used to test the alignment of the primer-sets to precise gene
loci. The primers sequences were submitted to and synthesized by IDTDNA.com
(Coralvill,e Iowa). The primer sequences for the genes used in this study are listed in Table
1. The ATF3 and PRDM5 primers were generated by did not perform well following
analyses.
Table 1: List of Primer Sequences for Genes Used in This Study
Gene

Left Primer

Right Primer

Size of
Amplicon

MYBL1

AAGTCTGGGCTTATTGGACATAA

TGCAAGTATGGCTGCTACATG

202bp

ATF3

GCTCTTTTCCCCACCTGTCT

TTGGAAATCAAGGCACCATT

203bp

DDX58

GACAGAACTGCAGCCATGAC

AGGGGTACAAGCGATCCATG

277bp

E2F6

TCTACCTAATTGCTGTCTCCCA

CTGGAGAGAGGGCAAGGTAC

242bp

E2F7

CGCTAGACTTGGATATTTTGGGT

CCCCGACTCTTGTACCAGAA

199bp

FBXL13

GCCATTACCTGCACATTTTGGA

CAAACCAACGTGGAGGGTCA

246bp

FBXO8

ACCTCACTAGCCCTCATGTG

GGTTGCACACTGAAGCTTGA

271bp

FBXO32

AGATCCGCAAACGATTAATTCT

AGGGGGACCCTTCTGAAGT

273 bp

Linoo673

TGAAGGCTCGTGTTCTCCAT

AAGTGCCACAACCCCTGATA

220bp

NFE2L3

TGGGCAAAAGCGATTAAGGG

ACACTGTAGCTCCTATGGCA

280bp

PSPH

TGTAGAGCTGCTGGGAGAAC

ACAAAACTCTCCAGGAAATCGA

258bp

ZN75A

TCTCTTCACAGTAGCAGGCT

CCCTAGTGGTGGTTAACAAGAT

228bp

GAPDH

TCCCTGAGCTGAACGGGAAG

GGAGGAGTGGGTGTCGCTGT

217bp

MYBL2

GAGGGGGTCTGTGAATCTGA

CCATCCTAAGCAGGGTCTGA

265bp

KIF18b

GCTCTTTTCCCCACCTGTCT

TTGGAAATCAAGGCACCATT

203bp

TCF19

TCTTAGGGGAAGGGGAGAGA

GTCACAGCCATCACACTGGT

266bp
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Polymerase Chain Reaction
The polymerase chain reaction (PCR) was used to confirm the microarray data and
also demonstrate differential expression between genes in different samples. PCR was
performed using the cDNA products. Each PCR reaction contained 2ul of forward and
reverse primers (generated to be specific for the particular gene), 2ul of cDNA (generated
above), 10ul of 2x thermostable DNA polymerase I TAQ polymerase master mix (which
contained TAQ enzyme, dNTPs and TAQ buffer; Life Technologies, Carlsbad, California)
and water to 20ul. The samples were place in PCR quality tubes, placed in the Bio-Rad
Thermal Cycler (Hercules California) and processed for (a) 5 minutes at 95ºC degrees (b)
then 30-32 cycles for 30 seconds at 95ºC, followed by 30 seconds at 58ºC degrees, then 30
seconds at 78ºC.
Gel Electrophoresis
A 2% agarose gel was utilized for analysis the PCR products. The gel was prepared
using 2 grams of agarose, added to 100ml of 1X Tris/Borate/EDTA (TBE) buffer. This
solution was microwaved, cooled, and 1ul Ethidium Bromide (EtBr) added, before pouring
into the gel chamber. Ten microliters of the PCR product and 2ul of sample buffer were
loaded onto the gel for electrophoresis.
Densitometer
The gels were viewed on the Licor, and the intensity of amplicons were analyzed
using software available on Licor. All the values were normalized compared to the control.
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shRNA Knockdown of MYBL1 in MDA MB231 Cells
The MYBL1 shRNA Lentiviral particles and the scramble control particles were
purchased from Origene (Cat # TL303089V; Rockville Md, USA). Four MYBL1 target
specific particles (packaged from the pGFP-C-shLenti vector; labeled LVA, LVB, LVC,
LVD) were supplied by Origene and screened for their efficiency to suppress expression
of the MYBL1 transcript. The lentiviral particles were transduced into MDA MB231
TNBC cells (at a MOI of 10:1) and screened to determine the sequence most effective at
down-regulating the MYBL1 transcript. MDA MB231 cells were incubated with the
targeted or scrambled viral particles for 72 hours in the presence of polybrene (sc-134220;
Santa Cruz Biotechnology, Dallas TX, USA) in complete cell culture media. Lentiviral
particles were removed, and fresh media was added to the cells. The transduced cells were
selected following growth in 1ug/ml puromycin (CAS 53792; Santa Cruz Biotechnology,
Dallas TX, USA). LVA particles, identified by the
TCTGATCCTGTAGCATGGAGTGACGTTAC sequence, demonstrated the most
significant down-regulation of MYBL1 mRNA, as a result this preparation was used for
the future experiments. Cells transduced with LVA, and the scrambled control sequence
were maintained in the presence of puromycin.
Processing of GEO Datasets
Experimental results from thousands of different types of experiments are
searchable and available in GEO available via National Center for Biotechnology
Information (NCBI, Bethesda, Maryland). Two datasets were found, examined for quality,
and extracted for use in this current project. The MCF7 ESR1 shRNA data set was
GSE37820. The MCF7 cMYB siRNA dataset was GSE21371.
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The datasets were loaded into the GEO2R online analysis tool, supplied by NCBI,
which allowed for differential gene expression analyses. Using GSE37820 as an example,
(a) MCF7 microarrays from scrambled shRNA preparations (control) were compared to
(b) MCF microarrays from ESR1 shRNA preparations. T-test – like analyses were
performed to compare transcript levels across thousands of genes. Genes displaying a
difference in transcript levels are considered differentially expressed. The data are sorted
based on fold change and statistical significance. When processing the GEO knock-down
dataset, very few genes were identified as differentially expressed, so a decision was made
to ‘relax’ the fold change stringency, prior to selection. The analyses conditions were also
relaxed if independent datasets showed evidence of differential expression. The datasets
can be further compared using MolbioTools
(http://www.molbiotools.com/listcompare.html) which allows for gene lists comparisons.
Microarray and Data Analyses Continued
RNA purified from MDA MB231 preparations transduced with either scrambled or
LVA shRNA were shipped overnight to the University of Texas Southwest Core Facility
(UTSW; Dallas Texas, USA). The aRNA was prepared by the UTSW core facility and
hybridized to the Affymetrix Clarion microarray gene-chip which includes ~186,000
probe-sets (i.e., transcripts, splice variants, siRNA and SNORna). The CEL intensity files
were made available to our laboratory, and data analyses was performed (at TSU) using
the Affymetrix TAC 4.0 software (Thermo Fisher Scientific, Waltham Mass). CEL
intensity results were normalized using functions in Robust Multi Array (RMA) program
and the differentially expressed genes were generated following Limma Bioconductor
analyses.
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Probe-sets that displayed at least a 4-fold difference in expression between the
MYBL1 LVA preparation compared to the scrambled sequence were selected for analyses.
A lower differential expression threshold (of 2x) was used for selection of the microRNA
(miRNAs), as the miRNAs were also screened via TargetScan analyses [41] to identify
their predicted nucleotide targets. The p-values were not generated by the TAC 4.0 program
as two Clarion microarrays were hybridized and subsequently processed to identify the
differentially expressed genes. Differentially expressed candidate genes were also
examined using Gene Ontology [42] analyses and by comparison to the gene expression
patterns in both untreated cell lines and patient samples. Transcript plots and analyses were
performed using Microsoft Excel. Comparisons between genes on the various differentially
expressed gene-lists were performed utilizing the Molbio-tools
(http://www.molbiotools.com/listcompare.html). Protein: protein interactions were
performed using the Search Tool for the Retrieval of Interacting Genes/Proteins
(STRINGTM) program [43]. STRINGTM analyses are based on interrogation of millions of
data generated experimentally, theoretical, and published.
Western Blotting
Log phase cells were washed with cold phosphate buffered saline (PBS), placed on
ice and scraped using cold Radioimmunoprecipitation assay (RIPA) lysis buffer (Santa
Cruz Biotechnology, Dallas TX, USA). The supernatants were mixed in the cold room and
centrifuged to collect solubilized protein preparations. Protein concentrations were
determined using the Pierce Bicinchoninic Acid Kit (BCA) (as suggested by ThermoFisher
Scientific, Waltham Massachusetts). Up to 50ug/lane of the protein was calculated for
loading to a gel lane. Protein was mixed with sample buffer, heated and loaded for
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electrophoresed using protocols available at Novus Biologics (Novus Biologics Littleton,
Colorado).

The protein preparations were transferred to nitrocellulose and probed for

detection of specific proteins using antibody concentrations and incubation times as
recommendation of the suppliers.
Antibodies: Actin was used at a 1:104 dilution (NB600-501SS; Novus Biologicals
LLC, Littleton, Colorado). MYBL1 was used at a 1:500 dilution (sc-514682; Santa Cruz
Biotechnology, Santa Cruz, California). MYBL2 was used at a 1:500 dilution (sc-81192;
Santa Cruz Biotechnology, Santa Cruz, California). TCF19 was used at a 1:100 dilution
(sc-390923; Santa Cruz Biotechnology, Santa Cruz California). KIF18b was used at a
dilution of 1:1000 (A303-982A; Bethyl Laboratories, Montgomery, Texas). Secondary
horseradish peroxidase conjugated Anti mouse (HAF007; R and D Systems, Minneapolis
Minnesota) and Anti Rabbit (NBP-2-30348H; Novus Biologicals LLC, Centennial,
Colorado) antibodies were used at a dilution of 1:4000. Western blotting results were
visualized with the Clarity Western ECL substrate (Bio-Rad, Hercules, California) on a LICOR digital imaging system (LI-COR Biotechnology, Lincoln, Nebraska).

CHAPTER 4
RESULTS AND DISCUSSION
Results generated by the microarray platform should only serve as a starting point
towards identifying potential candidates identified as differentially expressed genes.
Microarray data must be validated. As validation of the expression patterns, gene
expression levels should be compared to independent datasets and patient samples, and
transcript levels experimentally validated via PCR and protein analyses via western or
immunohistochemistry at a minimum. If a gene demonstrates the same pattern across all
analyses, it can be considered a reliable candidate for further study. In summary, the
purpose of these analyses is to identify genes that demonstrate a reliable pattern of
differential gene expression, across all the analyses, not just one experiment or one method
of analyses.
The main focus of our laboratory revolves around characterizing TNBC. These
cancers have poor 5-year survival, are over-represented in women of African-descent, and
unlike receptor-positive patients, there are few therapeutic options for TNBC patients [44].
Although several genes are being studied as possible therapeutics targets, to date, none are
being used as consistent therapy. TNBC patients are generally treated with the less specific
chemotherapy and radiation therapy. As a result, we are studying MYBL1 with the
objective of identifying novel genes that are enriched in these cancers, so that the genes
might be considered for more extensive studies; and if reliable, even as future therapy in
TNBC.
30
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As mentioned, this study is partitioned into Part 1 and Part 2. Both parts involve
analysis of gene expression when MYBL1 is down-regulated with the goal of identify
genes either directly or indirectly affected by down-regulation of MYBL1.
The difference between the two sections are the host cells and the primary genetargeted-for-silencing. In Part 1, the host cell is the MCF7 luminal cancer, and the gene
targets are ESR1 or cMYB. For Part 2 the host cell is the MDA MB231 cells, and the target
gene is MYBL1, which is more directly aligned with the focus of our laboratory. In
designing these experiments, we recognized that our approach would allow identification
of genes associated with luminal cancers (Part 1 ) and TNBC (Part 2). Towards the end of
this section, we speculate as to which family of genes might be associated with MYBL1 in
both luminal and TNBC. As expected, because the target cancer cells are so different, there
is little to no over-lap between MYBL1 associated genes in luminal and TNBC samples.
Results from Part 1 Studies
Reliable differentially expressed genes can only be identified by examining the
genes across different experimental platforms in search for a consistent pattern of
expression. For the Part 1 study, thirteen genes were initially identified as common between
the MCF7 ESR1 silencing datasets and the MCF cMYB silencing datasets (Table 2).
Thirteen genes were chosen following comparisons between the ESR1 and cMYB datasets,
however upon further analyses the number was even smaller. Based on their levels of
differential expression, MYBL1, DExD/H-Box Helicase 58 (DDX58), Elongation factor 7
(E2F7), Long Intergenic Non-Protein Coding RNA 673 (Lin00673), F-Box and Leucine
Rich Repeat Protein 13 (FBXL13), Phosphoserine Phosphatase (PSPH), and Activating
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transcription factor (ATF3) demonstrated significant differential transcript levels across
both silencing experiments as determined by their fold-change on the microarray platform.
All of the genes were not significantly differentially expressed, still they were
analyzed for their expression in patient samples (Figure 9). The Zinc Finger Protein 436
(ZNF436) and Zinc Finger Protein 75a (ZNF75A) genes were not in the patient datasets,
so they were not represented in the Hierarchical cluster analyses. Judging from the cluster
analyses, consistent with the results in Table 2, MYBL1, E2F7 and PSPH display the
strongest differential expression (with E2F7 and PSPH demonstrating a pattern similar to
MYBL1). This was determined by comparing the intensely of the red color in the cluster
analyses and the ‘clustering’ between MYBL1, E2F7 and PSPH. The genes in Table 2 were
also examined for their expression in Dr Player’s 2010 cell line dataset (not published).
Again, E2F7 demonstrated a pattern of expression similar to the MYBL1 profile in the cell
line datasets (Figure 10). The Dr Player’s 2010 cell line dataset and other independent
breast cancer datasets were used for comparison to the GEO datasets during the geneselection process. Dr Player’s 2010 dataset show low transcript levels and small (although
significant) differences between gene expression, which likely (in part) contributes to the
poor performance of the so-called 13-gene list.
For PCR analyses, ZNF436 was not in the cell line dataset, and we could not
generate quality PCR primers for ATF3 and PRDM5, so they were excluded from analyses.
Nonetheless, judging from the cell line data, E2F7 demonstrated a pattern of expression
consistently over-expressed with MYBL1 in the TNBC and MCF7 cells (Figure 11). This
was determined by visual inspection. A more reliable conclusion must involve
densitometer. These data suggested that our initial selection was either poor, or a more
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stringent selection method should have been used. The E2F7 gene did appear somewhat
promising, but further studies must be performed. E2F7 belongs to the E2F family of
transcription factor genes.
The E2F family of genes are involved in p53 regulated cell cycle signaling [45-47].
And previous data show E2F7 over-expression in breast cancer [48]. We are not suggesting
this is the case, here, because the current data only serves as an observation at this point. If
our current data prove to be reliable (i.e., upon repeat experimental analyses), the data can
serve to describe MYBL1 regulation of (or with) E2F7 under our experimental conditions.
Further analyses of E2F and other genes are included in the sections below. Early in the
analyses, the PSPH gene appeared to be a promising gene candidate, but the PCR results
were not reproducible, so the gene was not considered further. This is the purpose of the
screening process, which is to eliminate genes that do not reproducibly validate.
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Table 2:

Initial List of Genes Identified as Common Between the MCF7 ESR1
shRNA Compared to MCF7 cMYB siRNA. The Significance cut-off is
>2-fold with p Value <0.05.
Gene Description

Symbol

Fold
P Value
Difference
2.14
0.000193

V-Myb A vian Myel oblast Viral Oncogene
Homolog Like 1
Activating transcription factor 3

MYBL1
ATF3

2.1

0.00935

DExD/H-Box Helicase 58

DDX58

2

0.0037

Elongation factor 6

E2F6

1.2

0.0274

Elongation factor 7

E2F7

3.6

2.29E-03

F-Box and Leucine Rich Repeat Protein 13

FBXL13

2.5

0.0124

F-Box Protein 8

FBXO8

1

0.00248

F-Box Protein 32

FBXO32

1

5.76E-01

Long Intergenic Non-Protein Coding RNA 673

Linoo673

2.1

0.0117

Nuclear Factor, Erythroid 2 Like 3

NFE2L3

1

1.71E-02

PR/SET Domain 5

PRDM5

1

0.000906

Phosphoserine Phosphatase

PSPH

6.9

3.72E-01

Zinc Finger Protein 75a

ZN75A

1.3

0.0283

Zinc Finger Protein 436

ZN436

1

0.632

35

Figure 9:

Hierarchical Cluster of Maire Patient Data-set
Select genes were analyzed for their expression pattern in patient
samples. Not all genes were present in the patient dataset. Red bar
across the top designates TNBC patient samples ‘clustering together’
based on gene expression. Red regions within the plot represents higher
level of gene expression. Green indicates lower gene expression levels.
Note the region under the bar (i.e., TNBC) shows high gene expression.
PSPH, MYBL1, LINOO673, E2F7, NFE2L3, FBXL13, PRDM5, E2F6,
FBX08, DDX58 and ATF3 genes are examined in this patient dataset.

Figure 10:

Microarray Analyses of Select Genes in Player (2010) Cell Line
Dataset. Plot of Transcript Levels
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Figure 11:

PCR Performed to Experimentally Screen Select Genes
(a) Select genes were analyzed in 3 cell lines.
(b) Certain genes analyzed in the top panel were selected for repeat
analyses. Only the E2F gene appeared to demonstrate a
reproducible pattern of expression similar to that observed for
MYBL1.

As mentioned, we initially selected 13 genes common to ESR1 and cMYB
knockdown studies in MCF7. But upon inspection (a) all were not truly differentially
expressed (b) all did not validate or (c) were not represented in particular samples, or (d)
gene primers were not successfully generated (like with ATF3 and PRDM5). So, the list
of initial genes decreased from 13—to—11—to—10—to—6—1 gene, the E2F7 gene.
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Please note that this pattern of screening is common to DNA microarray. The
microarray is a useful experimental platform, but it is only used as a tool to identify
potential candidate genes. Even with this explanation, a good portion the responsibility lies
with our selection process. Only genes displaying substantial different expression should
have been initially selected.
Genes were only considered for further study if they displayed a consistent
experimental pattern, like that observed for E2F7. E2F7 appeared over-expressed with
MYBL1, suggesting co-expression and/or co-regulation. The E2F family of genes are
classified as transcription factors involved in transcription and proliferation events, so it
will not be surprising if MYBL1 is found to associate with E2F7. Lui et al. [48] found that
E2F7 gene was over-expressed in breast cancers. In addition, data show a significantly
strong relationship between MYBL1 and an E2F family member, E2F4 in cell cycle
signaling [49]. Our data will have to be repeated using samples other than those used in
this study before we can make definitive statements related to E2F7 (or other E2F family
genes) and MYBL1.
Part 2 shRNA Knockdown of Mybli in MDA MB231 TNBC CELLS
Since identifying MYBL1 over-expressed in TNBC, we have been concerned with
further characterizing the gene in these cancers. Part 2 of this current project will allow for
a better understanding of MYBL1 in TNBC.
Origene guaranteed one lentiviral preparation suitable for knock-down, so all were
screened to select for the one suitable for knock-down of MYBL1 gene in MDA MB231
TNBC cells. The sequences for the lentiviral preparations are listed in Table 3. The five
MYBL1 shRNA viral particle samples (sequences) were obtained from Origene, including
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a scrambled lentiviral control, and shRNAs corresponding to 4 different regions of the
MYBL1 nucleotide sequence. The MYBL1 shRNA preparations were labeled A-D. The
MYBL1 shRNA preparations were screened to determine which effectively decreased
expression of the MBYL1 in MDA MB231 TNBC cells. When LVA, LVB, LVC and LVD
were transduced into MDA MB231 TNBC, data show the LVA preparation was most
effective at KD of MYBL1 (Figure 12). As a result, the LVA preparation was utilized in
subsequent experiments, since it demonstrated substantial downregulation of MYBL1 gene
in MDA MB231 cells.
Table 3: Five MYBL1 shRNA Viral Particle Samples (sequences)
MYBL1 Lentiviral
TL303089VA

Sequence
TCTGATCCTGTAGCATGGAGTGACGTTAC

TL303089VB

CTTGTAATGGTGGCAACAGTGAAGCTGTT

TL303089VC

TAGCACTCCACCAGCCATCCTCAGAAAGA

TL303089VD

CAGGCACTCAACTGTTGACTGAAGACATT
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Figure 12:

Analyses of shRNA Scramble Sequence and MYBL1 shRNA Particles
to Screen for the Sequence that Most Effectively Decreases MYBL1
Expression in MDA MB231 Target Cells

Transcripts and Protein Levels Validation for Both Scrambled and LVA Sequences
To further evaluate the efficiency of the KD, we examined the transcript and protein
levels for the scrambled control compared to the LVA sequences in MDA MB231
transduced cells. The scrambled control served as a negative control and the LVA
preparation contained the shRNA MYBL1 target sequence. The transcript levels were
determined using PCR and protein expression levels were determined using Western
blotting analyses. Our data showed that LVA in MDA MB231 cells led to substantial KD
of MYBL1 transcript and protein levels compared to the scrambled control sequence
(Figure 13). The transcript levels are displayed in the top panel and the protein levels are
displayed in the bottom panel). MYBL1 levels in untreated MDA MB231 cells served as
positive controls for MYBL1 transcript and protein levels. Substantially high levels of
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MYBL1 transcript and protein are expressed in the MDA MB231 cells that were not treated
with lentiviral particles.

Figure 13:

Transcript and Protein Analyses of MYBL1 LVA shRNA Preparation
to Demonstrate Knock-down Efficiency
Three MDA MB231 preparations were examined for transcript or
protein levels. MDA MB231 preparations containing Scrambled
control, MYBL1 LVA or untreated MDA MB231 cells were
examined. The transcript analyses are in the top panel and the protein
analyses are in the bottom panel.

Gene Microchip Analysis
MDA MB231 cells were transduced with MYBL1 shRNA or scrambled control
sequences, and total RNA preparations were shipped to UTSW for Clarion microarray
hybridizations. Following microarray, the differentially expressed cells were determined
using the TAC4 program downloaded from Affymetrix.com.
A plot of the differentially expressed genes are represented as a Scatter plot in
Figure 14. The over-expressed probe-sets are represented in red and down-regulated probe-
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sets in green. The probe-sets include transcripts, splice variants and small RNAs. About
6000 probe-sets are represented in the Scatter plot. When the dataset is processed to remove
noise or background, the data-set decreases by10x to ~600 differentially expressed probesets. Table 4 was extracted from the TAC4 analyses to demonstrate how the gene
expression values are displayed by the TAC4 software.. The transcript or probe-set levels
are displayed as log 2 values to represent the signal intensity of the particular probe-set.
We converted the TAC4 values using an antilog calculator. As example, MYBL1 transcript
levels in the scrambled control is 4705 and 1024 in the knock-down sample; this shows a
decrease by >4 fold. Background level on the microarray is generally around 200. Note the
transcript values for MYBL2. Data presented here are the first to demonstrate regulation
of MYBL2 by MYBL1. Except for the antilog values, all of the calculations presented in
this figure are performed by TAC4. Even though samples like miR222 and SNORA30
show incredible differential expression, it is impossible to examine all of the probe-sets
that appear ‘interesting’. Although ~600 differentially expressed data points are a
manageable number to study, additional filters were performed to identify gene-set
enrichment. It is beyond the scope of this study to examine a vast number of genes.
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Figure 14:

Clarion Microarray Gene-chip Scatter Plot to Demonstrate
Differential Gene Expression
Differentially expressed probe-sets were selected based on
pvalue<0.05 and >2-fold difference between shRNA scramble vs
MYBL1 shRNA (LVA). Red represents over-expressed and green
represents under-expressed probe-set levels.
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Table 4:

Figure 15:

Example of the Data displayed by TAC4 and Also the Microarray
Transcript Levels for MYBL1, MYBL2 and small RNAs in Scrambled
Compared to LVA.

Gene Ontology to Determine Gene Set Enrichment in the Microarray
Dataset
A shortened gene list of differentially expressed genes show
enrichment of genes enriched for cell cycle signaling processes. These
genes are plotted in Figure 16.
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After filtering based on >4-fold expression, the shortened gene list was examined
using Gene Ontology and genes either directly or indirectly involved in cell signaling were
identified (Figure 15). This shortened dataset included MYBL1, MYBL2, TCF19, KIF18B
and other genes. Based on our interest, statistical significance and Gene Ontology,
transcript analyses of our gene candidates are plotted in Figure 16.
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Figure 16:

Final list of Candidate Genes Based on Differential Expression
Analyses of MYBL1 shRNA Compared to Scrambled Control
Data extracted directly from microarray results. (a-d) Transcript
levels are plotted. Blue bars represent transcript levels for the
scrambled control and orange bars represent the transcript levels of
the MYBL1 shRNA sample

MDA MB231 cells are negative for cMYB, ESR1, PGR and HER2, as a result,
these genes served as quality controls for the performance of lentiviral particles and the
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microarray (Figure 16a). Thus far the most promising genes in Part 2 of this project are
MYBL2, TCF19 and KIF18B. Our laboratory is in the process of examining the
relationship between MYBL1 and the genes included in Figure 16b-d. In separate studies,
data show MYBL1, MYBL2, TCF19 [50] and KIF18B [51] are involved in cell cycle
processes. As validation, STRINGTM analyses demonstrate significant protein: protein
interactions between the genes (Figure 17). Along with our 4 genes, STRINGTM show close
relationship with LIN9 and CCNB1 cell cycle signaling genes.

Figure 17:

STRING™ Analyses Demonstrating Significantly Relevant Relations
Between MYBL1, MYBL2, TCF19 and KIF18b
There are strong relationships between MYBL2 and TCF19 and
KIF18b based on published data. MYBL1, MYBL2, TCF19 and
KIF18B were entered into STRING™ to determine other genes
documented as associated.

MYBL1, MYBL2, TCF19 and KIF18B levels were examined for expression of
RNA transcript and protein levels (Figure 18) in untreated MC10A, MCF7 and MDA
MB231 cell line preparations. Overall, MYBL1, MYBL2, TCF19 and KIF18B RNA and

47
protein levels were over-expressed in TNBC compared to the non-tumor MCF10A
consistent with the KD data that show co-ordinate expression of the four genes.
KIF18B is over-expressed in MDA MB231. KIF18B is a kinesin motor protein
involved in chromosome motility [52], and Wolter et al [53] show that kinesins are
regulated by MYBL2. A similar signaling process could occur in TNBC. We can go one
step further and speculate that over-expression of KIF18B with MYBL1 and MYBL2 in
TNBC contributes to the motility and subsequent metastatic potential of TNBC cells. We
are considering experiments that will address this possibility. As for TCF19, both TCF19
[54] and MYBL1 are transcription factors and have been independently shown to be
involved in cell cycle signaling events. It could be that MYBL1 (MYBL2) and TCF19
genes cooperate in TNBC cell cycle signaling processes. The differential expression of
these genes in TNBC suggest their involvement in the cancers. Whether or not this is a
strong driving force must be determined.
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Figure 18:

PCR and Western Experimental Gel Analysis of Candidate Genes
Using Cell Line Samples
(a) transcript analyses of MYBL1, MYBL2, TCF19, KIF18B and
GAPDH control in MCF10A (basal non tumor), MCF7 (luminal) and
MDA MB231 (TNBC).
(b) protein analyses of MYBL1, MYBL2, TCF19, KIF18B and actin
control in MCF10A (basal non tumor), MCF7 (luminal) and MDA
MB231 (TNBC).

As further validation, MYBL1, MYBL2, TCF19 and KIF18B transcript levels were
examined in GEO (previously published) patient datasets (figure 19). The results were like
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observed in the cell line preparations. MYBL1, MYBL2, TCF19 and KIF18B were overexpressed in cancer patient samples compared to the non-tumor transcript samples.

Figure 19:

Analysis of Candidate Genes in Patient Samples
(a) Maire TNBC dataset including normal and TNBC patient samples
analyzed for MYBL1, MYBL2, TCF19 AND KIF18B.
(b) Analysis of MYBL1, MYBL2, TCF19 and KIF18B in patient transcript
datasets. GDS2250 patient dataset retrieved from GEO including normal,
luminal, and basal-like TNBC samples.

Analyses of Genes Identified in Part I Compared to Part 2 of the Study
Certain genes identified as common to knock-down of ESR1 in MCF7 and cMYB
in MCF7 were examined to determine if the genes were affected by knockdown of MYBL1
in TNBC. The answer is “No” (Table 5).
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Of the original gene list, DDX58 and FBX08 were affected by knock-down of
MYBL1 in TNBC, but contrary to results observed in the Part 1 study, both genes were upregulated when MYBL1 was knock-down (in Part 2). DDX58 and FBX08 were affected
by MYBL1 KD, but direction of differential expressed differed. In Part 1, DDX58 and
FBX08 was down-regulated when MYBL1 was down-regulated. In Part 2, DDX58 and
FBX08 is up-regulated with MYBL1 KD which suggests a different pattern of regulation
or involvement in different signaling mechanisms.
In Part 1 of the study, E2F7 transcription factor was affected by knock-down of
ESR1 in MCF7 and cMYB in MCF7 and followed a pattern similar to MYBL1 in knockdown and untreated cell preparations. Although E2F7 was not affected by MYBL1 knockdown in Part 2, a transcription factor family member, E2F4 was affected by knock-down
of MYBL1 in Part 2 (Table 6). STRINGTM bioinformatic analyses show protein: protein
interactions between MYBL1, E2F4 and E2F7, so there is experimental evidence of a
relationship between MYBL1, E2F4 and E2F7. STRINGTM also show involvement of
p53 with these genes, and p53 was also affected by MYBL1 knock-down (Figure 20).
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Table 5:

Original List of 13 Genes Analyzed for Pattern of Expression in Part 2 Conditions

Gene Description

Symbol

V-Myb A vian Myeloblast Viral MYBL1

scramble

LVA KD

12.4

10.3 (-4.06)

NC

NC

10.95

11.98 (+2.05)

Oncogene Homolog Like 1
Activating transcription factor 3

ATF3

DExD/H-Box Helicase 58

DDX58

Elongation factor 6

E2F6

NC

NC

Elongation factor 7

E2F7

NC

NC

NC

NC

F-Box and Leucine Rich Repeat FBXL13
Protein 13
F-Box Protein 8

FBXO8

11.32

12.9 (-2.97)

F-Box Protein 32

FBXO32

NC

NC

Non-Protein Linoo673

NC

NC

Nuclear Factor, Erythroid 2 Like 3 NFE2L3

NC

NC

PR/SET Domain 5

PRDM5

NC

NC

Phosphoserine Phosphatase

PSPH

NC

NC

Zinc Finger Protein 75a

ZN75A

NC

NC

Zinc Finger Protein 436

ZN436

NC

NC

Long

Intergenic

Coding RNA 673
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Table 6: Data from MYBL1 knock-down in the MDA MB231 Cells
E2F4 and TP53 were Down-regulated. These Data Have Not Been
Experimentally Validated.
Scramble Transcript
Level LOG 2 Values
12.39

MYBL1 shRNA

13.12

Fold Change

Gene

10.79

-3.9x

E2F4

10.78

-5.07x

TP53

A

B
Figure 20:

STRINGTM Protein
Protein interaction determines a relationship between E2F4 (identified in
Part 2 study) and E2F7 (identified in Part 1 study). There is also protein:
protein interaction between E2F factors and MYBL1 and MYBL2 with TP53
in cell cycle signaling.
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For breast cancers, it could be that E2F7 functions with MYBL1 in MCF7 luminal
cells and E2F4 functions with MYBL1 in TNBC. Published data validate co-operation
between E2F4 and MYBL1 and MYBL2 in cell cycle processes dream [26, 46, 55], so this
part of the statement has been validated. Gene alignment studies show a 33% similarity
between E2F4 and E2F7, and common functional domains in both E2F factors (data not
shown). The E2F transcription factor data are purely speculative at this point; because even
though E2F4 showed knockdown in TNBC, and previous published data show coexpression with MYBL1 and E2F4, the E2E4 microarray data presented here was not
experimentally validated. Microarray data presented here show that KD of MYBL1 leads
to down-regulation of E2F4, but these data cannot address the mode of regulation. The
current study suggests that MYBL1 signaling processes are different in MCF7 and TNBC.

CHAPTER 5
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
The goal of this study is to (a) identify genes either regulated by or with MYBL1
in breast cancer in MDA MB231 TNBC cells (b) to further characterize TNBC and (c)
begin to address the role of MYBL1 in these cancers. Data by other investigators suggest
that the MYBL1 gene is involved in tumor progression in different cancers. Because
MYBL1 is an oncogene, and associated with cell cycle regulation, apoptosis, and
differentiation, we see it as a suitable biomarker to study in TNBC. The current study is
only the beginning. We are considering two approaches to further characterize MYBL1 in
TNBC. First, we will repeat the KD study as it is described here, but we will validate our
panel of genes utilizing additional cell lines and patient sample datasets. Second, the
MYBL1 KD studies can be expanded to examine the ability of MYBL1 to produce tumors
in a mice model. These studies are instrumental towards validating the role of MYBL1 in
tumor development. Following transplantation, if MYBL1 plays a role in tumor
development, KD of the gene will prevent tumor formation in the mice model.
For the current study, our data show that the initial hypothesis was not correct to
use DEG in ESR1 KD (MCF7) and cMYB KD (MCF7) datasets to examined and identify
genes that might be associated with MYBL1. Our data suggest that the MCF7 DEG are not
differentially expressed in TNBC. The Luminal cancer transcriptome is very different from
the TNBC transcriptome. Except for the E2F family genes, our data show that genes
54
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associated with MYBL1 in Luminal cancers differ from those associating with MYBL1 in
TNBC. We did find that MYBL1 KD in TNBC leads to KD of E2F4 and TP53. In addition,
STRINGTM analyses show there are associations between E2F4, E2F7, TP53 along with
MYBL1 and MYBL2. Much of the data are not experimentally validated, but we will
consider future studies to examine the role of E2F4 and E2F7 in TNBC tumors using
additional datasets. For future studies will also consider more stringent statistical selection
parameters to select for DEG, similar to the conditions used for the MYBL1 KD in TNBC.
For example, for KD of MYBL1 in TNBC we utilized a high, statistical cut-off (of 4-fold)
for selection of our candidate genes; a more reliable list of candidate genes can be identified
under these conditions.
In addition to the genes examined in this thesis, a number of small RNAs, including
microRNA(miRNA) and small nucleolar RNA (snoRNAs) were identified as differentially
expressed and could be involved in TNBC signaling mechanisms. Our microarray data
revealed mir222, snorA30, miR3942, miR4295, miR4418, and miR3661 as strong
candidates to consider for further studies. SnorA30 which is up-regulated by 50x and
mir222 is up-regulated by 40x and studies suggest mir222 is regulated by MYBL1 [32].
Nineteen genes were selected to study for their possible relationship to MYBL1 in TNBC.
Two genes, TCF19 and KIF18B, were selected for more immediate studies. We are
currently examining the possibility that MYBL1, MYBL2, TCF19 and KIF18b are
cooperating in key signaling processes in TNBC. Each gene was validated
bioinformatically using patient datasets and experimentally based on transcript and protein
levels in cell lines. We will continue these studies in addition to other studies with a goal
towards characterizing MYBL1 in TNBC.
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